EMERGENT BIOSOLUTIONS INC (EBS) Stock News
NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD
EBS Latest News, Press Relases and Analysis
Tuesday's after hours session: top gainers and losers
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Emergent BioSolutions Announces Stock Repurchase Program
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and...
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada...
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its...
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and provide trainings...
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that...
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell...
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing
For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.
Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2024.
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease...
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025...
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an increase in...
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Africa CDC’s support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of...
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute...
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704...
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and...